Evidence map›Paper›PMID 41970643›Full record

ReviewFrontiers in genetics2026

Tumor microenvironment-induced epigenetic reprogramming of Tregs and its impact on immunotherapy.

Wenhao Li, Jiyu Tong

Abstract readReview
In one paragraph

Review in Frontiers in genetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Wenhao LiLaboratory of Epigenetics and Immunology, West China Institute of Women and Children's Health, NHC Key Laboratory of Chronobiology, State Key Laboratory of Biotherapy, West China Second University Hospital, Sichuan University, Chengdu, China.
Jiyu TongLaboratory of Epigenetics and Immunology, West China Institute of Women and Children's Health, NHC Key Laboratory of Chronobiology, State Key Laboratory of Biotherapy, West China Second University Hospital, Sichuan University, Chengdu, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The tumor microenvironment (TME) represents a complex system comprising various cells and extracellular matrix components that play a crucial role in tumor initiation and progression. While recent therapeutic strategies for predominantly focus on targeting tumor cells, their impact on other cellular components in the TME, such as regulatory T (Treg) cells, remains insufficiently understood. The cellular components of the TME include tumor cells, immune cells, tumor-associated stromal cells, and myeloid-derived suppressor cells. Notably, the role of Treg cells in tumor therapy has emerged as a significant research area of focus in recent years. Regulatory CD4

Indexed as

epigeneticepigenetic regulationTregstumor macroenvironmenttumor therapy

Identifiers

PMID41970643
PMCPMC13065300

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.